Private investors considering Novo Nordisk (NYSE:NVO) should approach with measured optimism.
The Danish drugmaker is a global leader in the fast-growing obesity market, but Morgan Stanley believes the near-term outlook is mixed.
While demand for weight-loss drugs remains strong, the bank has kept its rating at 'equal weight' and nudged its price target down to DKr550, citing short-term uncertainty in the US market.
Novo is betting on a second-half rebound for Wegovy, its flagship obesity treatment, as patients move away from cheaper compounded versions and towards branded prescriptions through cash payment or insurance plans.
Shift not guaranteed
But Morgan Stanley notes that this shift is not guaranteed. Many telehealth platforms have built significant revenue streams on compounded semaglutide and may not give up market share easily. Moreover, patients may hesitate to pay full price out of pocket or face insurance barriers.
The company is gradually repositioning itself to function more like a consumer health brand, engaging patients directly and leaning into pharmacy and digital distribution.
This could prove to be a smart strategy in a market with long-term structural growth. However, pricing pressure from Eli Lilly and uneven patient behaviour could weigh on performance in the short term.
Morgan Stanley is more bullish on the longer-term picture. Novo’s innovation pipeline remains a key strength, particularly its development of oral formulations and next-generation treatments like amycretin, which could offer superior efficacy and durability.
If these products succeed, Novo’s leadership in the metabolic health space would be further cemented.
No rush
Still, Morgan Stanley advises investors not to rush. While Novo remains a high-quality business with a dominant market share and strong fundamentals, the path to the next leg of growth may not be smooth.
For now, it is a case of waiting to see whether Wegovy’s second-half sales can deliver the results that management is counting on. Until then, portfolios may be better served staying lean.